Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Investing Activities (2017 - 2025)

Aclaris Therapeutics has reported Cash from Investing Activities over the past 9 years, most recently at $10.4 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at $10.4 million for Q4 2025, up 111.69% from a year ago — trailing twelve months through Dec 2025 was $48.4 million (up 169.32% YoY), and the annual figure for FY2025 was $48.4 million, up 169.32%.
  • Cash from Investing Activities for Q4 2025 was $10.4 million at Aclaris Therapeutics, down from $13.8 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for ACRS hit a ceiling of $32.5 million in Q3 2023 and a floor of -$88.7 million in Q4 2024.
  • Median Cash from Investing Activities over the past 5 years was $2.7 million (2022), compared with a mean of -$6.5 million.
  • Biggest five-year swings in Cash from Investing Activities: soared 2573.29% in 2023 and later tumbled 1275.14% in 2024.
  • Aclaris Therapeutics' Cash from Investing Activities stood at -$9.2 million in 2021, then skyrocketed by 129.45% to $2.7 million in 2022, then skyrocketed by 179.42% to $7.6 million in 2023, then tumbled by 1275.14% to -$88.7 million in 2024, then surged by 111.69% to $10.4 million in 2025.
  • The last three reported values for Cash from Investing Activities were $10.4 million (Q4 2025), $13.8 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.